Open AccessA randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B
Author(s) -
Ankur Jindal,
Ashish Kumar Vyas,
Manoj Kumar Sharma,
Guresh Kumar,
Shiv Kumar Sarin
Publication year - 2019
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/sjg.sjg_537_18
Subject(s) - medicine , telbivudine , gastroenterology , hbsag , hepatitis b virus , hepatitis b , clinical endpoint , randomized controlled trial , immunology , lamivudine , virus
Acute-on-chronic liver failure (ACLF-B) in spontaneous reactivation of chronic hepatitis B (SR-CHB) has high mortality. Tenofovir disoproxil fumarate (TDF) improves survival by ~40% in ACLF-B but is potentially nephrotoxic. Combining telbivudine (LDT) with TDF may negate this risk and could boost rapid viral clearance and improve clinical outcomes.